2020
DOI: 10.1186/s13039-020-00498-y
|View full text |Cite
|
Sign up to set email alerts
|

Prenatal diagnosis of rearrangements in the fetal 22q11.2 region

Abstract: Background: 22q11.2 deletion syndrome (22q11.2DS) and 22q11.2 duplication syndrome (22q11.2DupS) are the most common copy number variations in humans. The clinical phenotypes of these two syndromes are variable, and there are no large sample data on the prenatal detection rate for these two syndromes in the Chinese population. Results: We recruited 411 pregnant women who showed either abnormal prenatal ultrasound findings or positive prenatal BoBs™ results or who had given birth to a child with chromosomal abn… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…The first PGD by FISH for 22q11.2DS was reported almost twenty years ago, but currently it is very rarely used [ 92 ]. Prenatal diagnosis is available by non-invasive methods: foetal ultrasonography and echocardiography, and invasive methods: chorionic villus sampling (CVS) or amniocentesis followed by FISH (fluorescent in situ hybridization), GCH or SNP-array [ 4 , 93 ]. It is possible to evaluate fetal cells collected through amniocentesis, typically performed at 15–18 weeks gestation, or through CVS at approximately 10–12 weeks gestation.…”
Section: Individual Levelmentioning
confidence: 99%
“…The first PGD by FISH for 22q11.2DS was reported almost twenty years ago, but currently it is very rarely used [ 92 ]. Prenatal diagnosis is available by non-invasive methods: foetal ultrasonography and echocardiography, and invasive methods: chorionic villus sampling (CVS) or amniocentesis followed by FISH (fluorescent in situ hybridization), GCH or SNP-array [ 4 , 93 ]. It is possible to evaluate fetal cells collected through amniocentesis, typically performed at 15–18 weeks gestation, or through CVS at approximately 10–12 weeks gestation.…”
Section: Individual Levelmentioning
confidence: 99%
“…Patients with a 22q11.2 duplication should be monitored for heart defects, palate abnormalities, feeding difficulties, neutropenia, hypocalcemia, changes in thyroid function, and hearing loss. Patients also have a high risk of developmental and cognitive delays which require early identification and therapy [22].…”
Section: Effect On Patient and Family Managementmentioning
confidence: 99%